Literature DB >> 8040015

Radiotherapy for nasopharyngeal carcinoma: shielding the pituitary may improve therapeutic ratio.

J Sham1, D Choy, P W Kwong, A C Cheng, D L Kwong, C C Yau, K Y Wan, G K Au.   

Abstract

PURPOSE: Nasopharyngeal carcinoma (NPC) is well known for its invasiveness and erosion of the base of the skull is not uncommon. Before the advent of computed tomography, the evaluation of the base of the skull was by plain radiography. Because of the low sensitivity of these investigations, traditional teaching has included the sphenoid sinus in the volume of irradiation. Increase in longevity of patients allows the manifestation and documentation of the long-term sequelae of irradiating the hypothalamic-pituitary axis and the temporal lobes. This study is an attempt to evaluate whether the hypothalamic-pituitary axis can be shielded from the target volume in a proportion of NPC patients. METHODS AND MATERIALS: One hundred fifty-two NPC patients with no evidence of erosion of the base of the skull and sphenoid, nor extension to the nasal fossa and ethmoid sinuses were randomized to receive standard radiotherapy covering the whole sphenoid sinus or radiotherapy using a modified technique that shields the pituitary and the anterior part of the hypothalamus. This modified technique also shields a large part of the lower temporal lobes that are otherwise covered by standard treatment portals. The characteristics and treatment of the two subgroups of patients were otherwise comparable.
RESULTS: At a median follow-up of 31.5 months, the tumor control between the two subgroups of patients were comparable (p = 0.3928). However, 8 of the 71 patients in the unshielded group had developed symptomatic neuroendocrine complications, while none of the other group did (p = 0.0061). Two patients developed secondary hypothyroidism, one patient developed oligomenorrhoea associated with raised prolactin, and five patients developed temporal lobe necrosis.
CONCLUSIONS: The protective effect on neuroendocrine complication of this shield was demonstrated at median follow-up of 31.5 months, and the local control was not jeopardized. Modification of treatment technique as presently described, which is applicable to one-third of NPC patients to improve the therapeutic ratio, is recommended for general use.

Entities:  

Mesh:

Year:  1994        PMID: 8040015     DOI: 10.1016/0360-3016(94)90556-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Update in pediatric nasopharyngeal undifferentiated carcinoma.

Authors:  Line Claude; Emmanuel Jouglar; Loig Duverge; Daniel Orbach
Journal:  Br J Radiol       Date:  2019-07-31       Impact factor: 3.039

2.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

3.  Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group.

Authors:  Anna Merlotti; Daniela Alterio; Riccardo Vigna-Taglianti; Alessandro Muraglia; Luciana Lastrucci; Roberto Manzo; Giuseppina Gambaro; Orietta Caspiani; Francesco Miccichè; Francesco Deodato; Stefano Pergolizzi; Pierfrancesco Franco; Renzo Corvò; Elvio G Russi; Giuseppe Sanguineti
Journal:  Radiat Oncol       Date:  2014-12-29       Impact factor: 3.481

4.  Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy.

Authors:  Guan-Qun Zhou; Xiao-Li Yu; Mo Chen; Rui Guo; Ying Lei; Ying Sun; Yan-Ping Mao; Li-Zhi Liu; Li Li; Ai-Hua Lin; Jun Ma
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

5.  Prognostic variables for temporal lobe injury after intensity modulated-radiotherapy of nasopharyngeal carcinoma.

Authors:  Mei Feng; Yecai Huang; Xigang Fan; Peng Xu; Jinyi Lang; Dian Wang
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.